IP Library Patent Application 18416210
Patent Application
App. No. 18/416,210

METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/416,210
Abstract

Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine or pharmaceutically acceptable salt thereof.

Claims (9)

1 . A method for decreasing the risk of death or prolonging the survival of a subject with ALS wherein the method comprises administering to the subject a composition comprising a therapeutically acceptable amount of pridopidine or pharmaceutically acceptable salt thereof.

2 . The method of claim 1 , wherein the method comprises administering the composition for at least 4 months, 6 months, 8 months or 10 months.

3 . The method of claim 1 , wherein the decrease in the risk of death is between 20%-90% compared to a subject not treated with pridopidine.

4 . The method of claim 1 , wherein the decrease in the risk of death is between 50%-70% compared to a subject not treated with pridopidine.

5 . The method of claim 1 , wherein the method prolongs the survival of a subject with ALS by at least 2 months, 4 months, 6 months, 10 months, 12 months, 24 months compared to a subject not treated with pridopidine.

6 . The method of claim 1 , wherein the amount of pridopidine or pharmaceutically acceptable salt thereof is administered daily, twice a week, three times a week or more often than once daily.

7 . The method of claim 1 , wherein the amount of pridopidine or pharmaceutically acceptable salt thereof is administered orally.

8 . The method of claim 1 , wherein the amount of pridopidine or pharmaceutically acceptable salt thereof administered is 10 mg per day to 90 mg per day.

9 . The method of claim 1 , wherein the pridopidine salt is pridopidine hydrochloride.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2024
From: HAYDEN, MICHAEL; GEVA, MICHAL
To: PRILENIA NEUROTHERAPEUTICS LTD.
Reel/Frame 066466/0219 →